As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Invasive fungal infections are another top concern, as outlined by the World Health Organization’s Fungal Priority Pathogens ...

As one of the leading causes of acute gastroenteritis worldwide, NoV is associated with a substantial healthcare burden.

Oral cefixime is a third-generation cephalosporin that has a similar antibacterial spectrum to ceftriaxone. Cefixime is ...

Revaccination at 12 months with the investigational respiratory syncytial virus (RSV) vaccine mRNA-1345 is well tolerated and supported for eligible older adults, according to study results presented ...

New IDWeek 2024 study reveals disparities in PrEP uptake across key U.S. populations. While overall PrEP usage has increased, ...

Clesrovimab, formerly known as MK-1654, is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody.

Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced the upcoming presentations of pemivibart data from ...

A new study presented at IDWeek 2024 reveals that race and socioeconomic vulnerabilities significantly impact vaccine uptake ...

ATI-1701 provides full protection against lethal tularemia in animal models after one yearCompany to provide update on tularemia vaccine ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announces new data ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...